Compare Standard Lithium Ltd (SLI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Sanofi SA — how do they compare? Standard Lithium Ltd trades at $2.41 (market cap $604.50M), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 172.5× Standard Lithium Ltd's market cap, and Sanofi SA pays a 5.55% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| SLI | SNY | |
|---|---|---|
Market Cap | $604.50M | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $52.34 |
52-Week Low | $1.93 | $41.33 |
Enterprise Value | $467.42M | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $2.41, down 4.74% on the day, with technical indicators showing a bullish trend despite recent price weakness. The company maintains strong analyst support with 100% buy ratings from 3 analysts, reflecting optimism about its South West Arkansas lithium project development. Recent earnings show improved performance with two consecutive quarterly beats, though the company remains unprofitable with negative ROE and ROA. Institutional interest is growing, with Amundi increasing its stake by 64.9% in Q1 2026 according to SEC filings.
The investment case centers on SLI's transition to production status with major project de-risking events, including a $225M DOE grant and construction contracts. However, significant execution risks remain as the company burns cash with negative operating cash flow. The path to profitability depends on successful project completion and lithium market conditions, creating both substantial upside potential and meaningful downside risk for investors.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
